Mark Ahn (via PR Newswire)

For­mer Gale­na chief Mark Ahn back in hot wa­ter as DOJ lev­els in­sid­er trad­ing charges for con­sul­tant work

When Mark Ahn de­part­ed trou­bled Gale­na Phar­ma­ceu­ti­cals back in 2014, he told in­vestors he look­ing to pur­sue oth­er “long-held” goals. Turns out one of those goals may al­leged­ly have been ped­dling stock based on in­sid­er in­fo.

The DOJ on Mon­day charged Ahn, Gale­na’s for­mer CEO, with two counts of se­cu­ri­ties fraud af­ter he al­leged­ly bought a biotech’s stock based on non­pub­lic in­for­ma­tion about the com­pa­ny’s in­tent to sell, which he ac­quired as a con­sul­tant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA